Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Clover Bio of Chengdu Completes $9.5 Million Series A for Biotech/Biosimilar Portfolio

publication date: Dec 14, 2017

Clover Biopharmaceuticals, a Chengdu biotech startup, completed a $9.5 million Series A financing led by Tianhe Life Sciences Venture Fund. Clover is developing a portfolio of novel biologic and differentiated biosimilar drug candidates. The company in-licensed rights to GenHunter Trimer-Tag© technology, which it uses to discover novel molecules for autoimmune diseases and cancer. It has also built a cGMP manufacturing capability for biologics, and expects to begin two clinical programs next year. The company plans to bring its novel, affordable drugs to China and global markets. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital